Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANK-101 in advanced solid tumors
NCT06171750Phase 1Recruiting
- Sponsor
- Ankyra Therapeutics
- Start
- Jan 2024
- Primary completion
- Apr 2027
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 1, open-label trial of tolododekin alfa in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and cutaneous squamous cell carcinoma (cSCC), sponsored by Ankyra Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 90 days, Treatment-Emergent Adverse Events at 90 days and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
tolododekin alfa
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06171750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171750.